COMP <GO>
CLH vs TMO // FORWARD P/E MULTIPLE
Clean Harbors Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: CLH 4
— TMO 10
▲ FORWARD P/E MULTIPLE LEADER: TMO
LAST: $302.12 (-2.33%) • MKT CAP: $16.31B
forward-pe
38.8x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
forward-pe
36.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLH VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLH | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 31.30% | 41.00% | -9.70 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.60% | 9.30% | +2.30 | CLH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 30.4x | -12.80 | CLH | /valuation <GO> |
| Free Cash Flow Yield | 2.71% | 2.40% | +0.31 | CLH | /fcf-yield <GO> |
| Operating Margin | 11.20% | 17.40% | -6.20 | TMO | /operating-margins <GO> |
| Net Profit Margin | 6.50% | 15.10% | -8.60 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 2.40% | 3.90% | -1.50 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.50 | 4.50 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.70% | +0.40 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.4 | 59.1 | -28.70 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.94 | +0.13 | CLH | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 38.8x | 36.3x | +2.50 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.31B | $262.22B | -$245.91B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLH REV | TMO REV | CLH GROSS % | TMO GROSS % | CLH FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.03B | $44.56B | 31.3% | 44.0% | $441.8M | $6.29B |
| FY 2024 | $5.89B | $42.88B | 31.0% | 44.0% | $345.5M | $7.27B |
| FY 2023 | $5.41B | $42.86B | 44.0% | 44.0% | $491.1M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLH // BETA 1.07
TMO // BETA 0.94